Evidence map›Paper›PMID 39070626›Full record

ArticleResearch square2024

Prevalence and Associated Factors of High-Risk Human Papillomavirus Infections among Human Immunodeficiency Virus-Infected Women in Lagos, Nigeria.

Kehinde S Okunade, Kabir B Badmos, Austin Okoro, Nicholas A Awolola, Francisca O Nwaokorie, Hameed Adelabu, Iyabo Y Ademuyiwa, Temitope V Adekanye, Packson O Akhenamen, Elizabeth Odoh and 5 more

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kehinde S OkunadeUniversity of Lagos.
Kabir B BadmosUniversity of Lagos.
Austin OkoroLagos University Teaching Hospital.
Nicholas A AwololaUniversity of Lagos.
Francisca O NwaokorieCollege of Medicine of the University of Lagos.
Hameed AdelabuUniversity of Lagos.
Iyabo Y AdemuyiwaUniversity of Lagos.
Temitope V AdekanyeLagos University Teaching Hospital.
Packson O AkhenamenLagos University Teaching Hospital.
Elizabeth OdohLagos University Teaching Hospital.
Chinelo OkoyeLagos University Teaching Hospital.
Alani S AkanmuUniversity of Lagos.
Adekunbiola A BanjoUniversity of Lagos.
Rose I AnorluUniversity of Lagos.
Jonathan S BerekStanford University School of Medicine.

Funding

Nigeria HIV Research Training ProgramD43TW010934 · FIC · EMORY UNIVERSITY · PI Ighovwerha Ofotokun · 2019 to 2026
$2.4M
COMParative ASSessment of p16/Ki-67 DUal Staining Technology in women living with HIV (COMPASS-DUST study)K43TW011930 · FIC · COLLEGE OF MEDICINE, UNIVERSITY OF LAGOS · PI KEHINDE SHARAFADEEN OKUNADE · 2022 to 2026
$500k
FIC NIH HHS D43 TW010934FIC NIH HHS K43 TW011930
6 · The paper itself

Abstract

Background: Given the synergistic relationship between human immunodeficiency virus (HIV) and human papillomavirus (HPV) infections, knowledge of the genotypic prevalence and associated factors of high-risk HPV (HR-HPV) among HIV-infected women is crucial for developing targeted interventions such as appropriate screening tests and effective genotype-specific vaccination. Objectives: We determined the prevalence of any HR-HPV and multiple HR-HPV infections and identified associated factors among a cohort of women living with HIV infections (WLHIV) in Lagos, Nigeria. Methods: This descriptive cross-sectional study analysed the data of 516 WLHIV who underwent cervical cancer screening as part of the Results: Among the 516 WLHIV enrolled (mean age, 46.5±7.3 years), the overall HR-HPV prevalence was 13.4% (95% CI, 10.6-16.6), disaggregated as 3.3% for HPV16/18 (95% CI, 1.9-5.2) and 11.6% for Conclusion: The findings of this study provide valuable insights into the epidemiology of HR-HPV infections and highlight the need for tailored interventions and continuous monitoring. By addressing these challenges through targeted screening, effective ART management, and vaccination programs, we can improve health outcomes and reduce the burden of cervical cancer in this vulnerable population.

Indexed as

Cervical cancerHPV genotypesLagosMultiple HPV infectionsScreenings

Identifiers

PMID39070626
PMCPMC11275992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.